DNA Funded, a retail funded-trading challenge brand associated with DNA Markets Group, is the subject of a series of customer reviews describing payout or account disputes near the point of profit. The parent group operates through Focus Markets Pty Ltd, which holds Australian Financial Services Licence 514425, according to the company disclosures and ASIC register cited in the supplied research. That is a verifiable regulatory connection for the brokerage entity; it should not be read as automatic regulatory approval of every separate simulated-trading challenge or its payout decisions.
The Trustpilot snapshot cited in the review material showed DNA Funded at 3.3 out of 5 from 85 reviews. One review dated 1 May 2026 says a trader made about $1,200 over a week, then had a payout denied while the firm cited different rule concerns during the dispute, including consistency, news trading and gap trading. Those are the customer’s account of the exchange; the public review does not include a full trading log or account-level decision file.
What the Payout Reviews Describe
Other 2026 reviews describe similar disagreements about the application of rules. A 5 June reviewer said an account was breached close to payout and alleged the firm was avoiding payment; that characterization is not independently established. A 12 March review describes a payout rejected over alleged hedging across related instruments, with the customer saying the firm’s interpretation differed from the published rules. A separate review dated 30 March says repeated violations reduced attempted payouts to zero and calls the rules contradictory.
A review dated 31 July refers to an earlier TradeLocker incident in which the customer says the platform executed incorrect lot sizes and caused losses. The reviewer says the firm declined a platform change and refund. The materials available here do not establish the technical cause or the company’s complete response, so that account should be treated as a reported dispute rather than a verified platform failure.
What the ASIC Licence Covers
Focus Markets Pty Ltd’s AFSL is a meaningful regulatory fact for services provided by that licensed entity. DNA Markets Group is a business name associated with Focus Markets, but a funded challenge may be a distinct product with different terms and legal relationships. Customers should read the entity named in their challenge agreement, identify who receives the fee and check the licence register for the exact service involved. A parent or affiliated company’s licence does not, by itself, settle which entity is responsible for a simulated account or a disputed payout.
No regulator determination concerning the customer complaints summarized above was identified in the linked material. The complaints are relevant to a prospective customer’s due diligence, but they are not findings that every breach decision was improper.
About DNA Funded
Product: Simulated funded-trading challenge and evaluation accounts.
Parent connection: DNA Markets Group is associated with Focus Markets Pty Ltd, AFSL 514425.
Trustpilot snapshot: 3.3 out of 5 from 85 reviews in the supplied research.
Reported issue: Customer disputes over payout decisions and alleged rule breaches.
Frequently Asked Questions
Is DNA Funded regulated by ASIC?
The supplied research identifies Focus Markets Pty Ltd, associated with DNA Markets Group, as holding AFSL 514425. That licence should be checked against the specific legal entity and service in a customer’s agreement.
Why do DNA Funded traders report payout denials?
Reviews cited in the supplied material describe disputes over alleged consistency, news-trading, gap-trading and hedging rules. The customers dispute how those rules were applied.
Does the parent’s ASIC licence guarantee a challenge payout?
No. A licence held by an affiliated brokerage does not automatically determine the terms or outcome of a separate simulated-trading challenge.
See the DNA Funded profile for directory information.